Silence Therapeutics plc
SLNHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeSilence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of. The company carries a $1.22B market cap, placing it firmly in the small-cap category. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases.
Market Cap
$1.22B
Beta
1.45
P/E (TTM)
—
P/E (Fwd)
-51.76
EPS (TTM)
$-1.29
EPS (Fwd)
$-0.38
ROE
-90.4%
ROA
-29.6%
Cash
$72.1M
Total Debt
$112,000
Free CF
-$23.6M
52W Change
175.5%
Annual Financials
Cash vs Debt
Where SLN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, SLN finished 107.86% above its 150-day moving average ($9.42) and 132.27% above its 200-day moving average ($8.43). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SLN overbought or oversold?
At the October 20, 2026 close, SLN's RSI(14) was 79.4, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Silence Therapeutics plc holds $72.1M in cash against $112K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$23.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -90.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $21.7M to $559K.
With cash comfortably exceeding debt, SLN has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Silence Therapeutics plc's trajectory.